← All trials
NCT03571256
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2018
- Primary completion
- Sep 25, 2019
- Completion date
- Dec 9, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- TevaLead sponsor
- TevaStudy director
- Nuvelution TS Pharma, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.